Novartis finds targeted prostate cancer therapy

Novartis said a prostate treatment that delivers radiation to specifically targeted cancer cells helped patients in a study that the Swiss drugmaker will use for U.S. regulatory approval.

The precision medicine, called Pluvicto, showed an effect on a form of survival without the disease worsening in patients who had already been treated with androgen-receptor pathway inhibitor therapy and whose prostate cancer had spread. The study is the second to show positive effects of the drug in an advanced clinical trial, Novartis said Monday.

Novartis plans to present the data to the U.S. Food and Drug Administration next year for regulatory approval.